

NGS Panels
Benefit from our medical expertise
and streamlined genetic testing

Working together for a
patients better tomorrow.

Next Generation Sequencing (NGS) Panels

CENTOGENE is fully committed to bringing the best possible diagnostic solutions to our patients and their families. We always strive to incorporate the latest in-house findings and medical research in our products to improve and ease the diagnostic odyssey of rare disease patients.

To reflect the fast-growing knowledge of complex associations of genes with diseases as well as to maximize clinical sensitivity, we have updated and significantly redesigned our Next Generation Sequencing (NGS) gene panels. The gene composition of each panel has been revised to meet the latest gene discoveries as well as to provide the highest clinical validity. Additionally, we minimized complexity and removed redundancy by creating phenotype-directed diagnostic panels, which include all relevant genes necessary for differential diagnosis of syndromes with overlapping phenotypes, therefore allowing the diagnosis of diseases that otherwise would be missed. This principle increases the clinical utility, de-risks panel choice, increases cost-effectiveness, and ultimately simplifies the diagnostic process.

When choosing one of our NGS panels, feel confident that you will receive high-quality sequencing combined with best data analysis and interpretation, which are documented in comprehensive medical reports. As always, CENTOGENE and our Customer Support Team is readily available to help in each step of the diagnostic process.

When to Choose a Panel?

Recommended when patients meet any of the following criteria:¹

- Genetically heterogeneous disorders where a similar manifestation might occur through different genetic mechanisms
- Phenotypes corresponding to disturbances of the same pathway
- Disorders sharing one manifestation with varying presentations
- Disorders with overlapping manifestations corresponding to differential diagnosis
- Disorders where multiple genes are linked to the condition
- Family history suggestive of a genetic condition, but without a precise diagnosis

¹ Genet Med. 2015 Jun;17(6):444-51. doi: 10.1038/gim.2014.122. Epub 2

Panel Features

COVERAGE	≥ 99.0% targeted regions covered at ≥ 20x
CNV ANALYSIS	Included in our panels at no extra cost
MITOCHONDRIAL GENOME	Mitochondrial genome added to relevant panels with a coverage of ≥ 98.0% target regions covered at ≥ 20x
VARIANTS	All single nucleotide variants described in HGMD and CENTOGENE's rare disease-centric Bio/Databank, including relevant deep intronic and regulatory variants
CLINICAL INFORMATION	Detailed and specific clinical information (i.e., HPOs) is required for variant interpretation and medical diagnosis
REPORTING	Pathogenic and likely pathogenic variants are reported following ACMG classification guidelines and according to the clinical information provided. Variants of uncertain significance (VUS) related to the described phenotype(s) of the patient or family members are reported only if the described phenotype(s) is not explained by detected pathogenic or likely pathogenic variant(s). VUS are not reported when there is insufficient clinical information, or in our Oncogenetic panels
COMPLEMENTARY ASSAYS	Our panels are reinforced when necessary with auxiliary assays
TAT	25 days

Some exceptions may apply. For complete information about our panels, please visit: www.centogene.com/diagnostics/ngs-panels

The CENTOGENE Advantage

MORE THAN STREAMLINED GENETIC TESTING. THE SUPPORT YOU NEED TODAY.

CentoCard®

Our quick, cost-effective, and hassle-free solution for shipment of clinical blood samples for genetic testing. CentoCard provides a single sample for complete patient diagnostics: enzyme assay, biomarker analysis, and genetic testing.

Extended Phenotyping

Structuring your patient's symptoms into Human Phenotype Ontology (HPO) terms ensures the best quality of clinical information for data interpretation.

Data Safety and Research Use

With transparent and easy-to-understand consent forms, your patients can make educated decisions without worrying about data protection. By consenting to the research and storage option, you and your patients will advance research, the understanding of rare diseases, and the quality of future diagnoses and therapies.

Multiomics Testing

We have pioneered a multiomic testing strategy – combining panel technology with biochemical testing. By starting out with a complete clinical picture, you can now direct patients to the most precise diagnosis and potential treatment options.

CentoPortal®

Our user-friendly and fully-secure online service www.centoportal.com is designed to assist in ordering tests, transferring patient data, administering patient's samples, and accessing your diagnostic reports 24/7.

Bio/Databank


Our rare disease-centric Bio/Databank with over half a million patients and more than 31 million unique variants enable world-class medical interpretation.

Clinical Studies and Pharma Partnerships

By participating in clinical studies, your patients benefit as they foster the development of new therapies and improved monitoring. Through pharmaceutical partnerships, we also leverage our expertise to speed up drug development in rare diseases.

World-Class Expertise

At CENTOGENE, we connect patients around the world to empower innovative solutions for the global rare disease community. With our unique expertise in rare disease diagnostics and insights from over half a million patients, we provide answers today so that your patients can have a better tomorrow.



● Broad disease panels
 ● Targeted panels
 ■ Targeted panels with complementary assays
 Related disease categories

NGS Panels

BENEFIT FROM OUR MEDICAL EXPERTISE AND STREAMLINED GENETIC TESTING

FOR ORDERING

www.centoportal.com

FOR MORE INFORMATION

www.centogene.com

CENTOGENE GmbH
Am Strande 7
18055 Rostock
Germany

CENTOGENE GmbH is a subsidiary of CENTOGENE N.V.

PARTNER SUPPORT

✉ customer.support@centogene.com

☎ +49 (0) 381 80 113-416

FOR US PARTNERS

✉ customer.support-us@centogene.com

☎ +1 (617) 580-2102

Rostock - CLIA #99D2049715



Cambridge - CLIA #22D2154474

